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ptimal Stent
xpansion and Complete
eointimal Coverage
oes This Association Make Sense?*
ary S. Mintz, MD, So-Yeon Choi, MD
ew York, New York
n this issue of JACC: Cardiovascular Interventions, Sera et
l. (1) report that stent underexpansion (analyzed using
ntravascular ultrasound) is associated with incomplete
eointimal coverage (determined by angioscopy) after
irolimus-eluting stent implantation; incomplete neointimal
overage is a pathologic risk factor for late stent thrombosis.
See page 989
or the same sized vessels, complete neointimal coverage
as associated with a larger minimum stent area (MSA)
hen compared with incomplete coverage. Besides the
ethodological limitations typical for any small study, does
his link make sense? The authors explain their findings by
iting animal study histopathologic data from the bare-
etal stent (BMS) era relating neointimal hyperplasia to
essel injury, especially to strut penetration into the media
2). They suggest that: 1) a larger MSA is inferential
vidence of vessel injury; and 2) with BMS this is “bad”
ince it leads to more restenosis while in drug-eluting stents
DES) this is “good” since it increases completeness of stent
trut tissue coverage.
We are not so sure. First, these histopathologic studies
re in BMS, not in DES; to our knowledge, the stepwise
elationship between an injury score and intimal hyperplasia
as not been confirmed in DES. Second, these studies are
ostly from nonatherosclerotic animal models. Third, in
ost-mortem human studies, only one-third of stents con-
act the media (3); moreover, stents do not penetrate the
edia at the site of maximum plaque burden, typically the
ite of the MSA. Fourth, even in BMS (with the exception
f the Hoffmann et al. study [4]), there is no consistent
vidence that a larger MSA is associated with a greater
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-p
ions or the American College of Cardiology.
From the Cardiovascular Research Foundation, New York, New York.eointimal response. Fifth, the relationship between injury
nd intimal hyperplasia in BMS is focal, on a slice-by-slice
r even strut-by-strut basis. Why should stent underexpan-
ion at the MSA site contribute to incomplete strut coverage
t other sites or throughout the stent?
Instead, we believe that other explanations are worth
xploring. For example, atherosclerosis, neointimal hyper-
lasia, and stent thrombosis predominantly develop at sites
f low wall shear stress that is inversely proportional to the
ube of the radius (5). Sukavaneshvar et al. (6) have
emonstrated that platelet-dependent thrombosis is pro-
oted by increasing radial transport of blood components
nd low wall shear stress. Low shear stress might be a risk
actor for stent thrombosis for as long as the mechanical
ause exists even though most reports related early stent
hrombosis to stent underexpansion (7,8). Thus, in BMS
tent underexpansion (and low shear stress) may result in
incomplete” endothelialization that may accelerate neoin-
imal growth (5,9). However, in DES the eluted drug
uppresses neointimal growth and re-endothelialization so
hat underexpansion may result in thrombus formation in
reas of low wall shear stress (10,11). While the primary aim
f DES is preventing vascular smooth muscle cell prolifer-
tion and migration, the eluted drugs also impair re-
ndothelialization leading to delayed arterial healing, in-
uced tissue factor expression, and a prothrombogenic
nvironment (12,13).
Angioscopy and optical coherence tomography are the
est clinical tools to evaluate tissue stent strut coverage
14–17), but they do not evaluate the function of the
ndothelium or even the existence of re-endothelialization;
e-endothelialization is below the current resolution of these
echniques. In addition, although 1 post-mortem study has
hown that the most powerful morphologic predictor of
tent thrombosis is tissue coverage (18), there is no strong
vidence that clinically detected incomplete stent strut cov-
rage leads to stent thrombosis. Many DES with incom-
lete strut stent coverage do not thrombose (15,17,19)
lthough subclinical stent thrombus formation may be
nder-recognized (20).
Mechanical factors such as stent underexpansion are more
mportant in early thrombosis, whereas patient factors such
s cessation of antiplatelet agents are more important in
ate/very late DES thrombosis (11). Studies have also shown
hat inflow/outflow disease or a larger residual reference
egment plaque burden is a risk factor for stent thrombosis
6–8). To that end, in the study by Sera et al. (1), stents
ith incomplete neointima coverage had a smaller distal
eference lumen area and a tendency for a greater distal
eference plaque burden.
There are many limitations to this study including the
ack of baseline pre-DES imaging. However, most impor-
antly, the authors only report 28 stented segments in 15
atients. Even in this very small study, most patients had
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996ultiple stented segments. Did individual stented segments
n the same patient behave independently or were they
nfluenced by patient-related factors; if there were 2 stents
n 1 patient, were they equally expanded and/or did they
ave similar neointimal coverage? For example, there was an
nteresting trend relating diabetes to neointimal coverage
hat was never explored. Another limitation is the assess-
ent of neointimal coverage by angioscopy (14,15). Using
ngioscopy, complete circumferential view of the entire
tent length may be prohibited by vascular tortuosity (15).
Furthermore, unlike animal models relating local neoin-
imal tissue versus focal vessel injury on a slice-by-slice or
trut-by-strut basis and pathologic studies showing hetero-
eneity of DES neointima, angioscopic classification of
eointimal coverage is global and not regional while stent
xpansion is evaluated at 1 slice—the MSA site. Especially
hen assessing the relationship between stent expansion,
eointimal hyperplasia, and thrombus formation, the intra-
tent “regional” environment (low shear stress) and blood
ow is more complicated and dependent on 3-dimensional
tent as well as inflow/outflow geometry (6).
The current study combined angioscopic and intravascu-
ar ultrasound findings. In the future optical coherence
omography, which can assess both MSA and strut-by-strut
eointimal coverage over the entire length of the stent
16,17) as well as other potentially important findings such
s stent-vessel wall malapposition and atherosclerotic and
eointimal plaque composition, may be preferred for such
tudies.
Nevertheless, Sera et al. (1) provide a novel explanation for
he relationship between stent underexpansion and stent
hrombosis—that stent underexpansion limits stent strut neo-
ntimal coverage and, therefore, could promote stent throm-
osis. Does their data and explanation make sense? Perhaps.
erhaps not. However, the authors provide another com-
elling reason to optimize DES expansion and not just
ettle for “good enough.”
eprint requests and correspondence: Dr. Gary S. Mintz,
ardiovascular Research Foundation, 111 East 59th Street, 11th
oor, New York, New York 10022. E-mail: gsm18439@aol.com.
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